VRXA VRXA
Company Profile ↓Company Overview
VRXA (VRXA) is a publicly traded company listed on with a market capitalization of $257.36M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -82.50% |
| 6 Months: | -82.94% |
| 3 Months: | -86.09% |
| 1 Month: | -39.93% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 92.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 23.43K |
| Cost of Revenue | - | 0 | 7.96K |
| Gross Profit | - | 0 | 15.46K |
| Operating Expenses | 16.66M | 28.92M | 66.23M |
| Operating Income | -16.66M | -28.92M | -66.22M |
| EBITDA | -15.81M | -26.88M | -64.91M |
| Interest Expense | 1.09K | 291 | 3.55K |
| Pretax Income | -17.66M | -28.75M | -67.01M |
| Tax Provision | -1.11M | -620.77K | -392.60K |
| Net Income | -16.54M | -28.13M | -66.61M |
| Diluted EPS | -0.12 | -0.20 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 91.94M | 84.77M | 80.82M |
| Current Assets | 11.88M | 5.61M | 2.88M |
| Cash & Equivalents | 11.35M | 5.36M | 1.61M |
| Inventory | - | - | - |
| Receivables | 257.76K | 174.87K | 1.17M |
| Total Liabilities | 36.81M | 53.71M | 96.59M |
| Current Liabilities | 1.61M | 2.55M | 6.61M |
| Long Term Debt | - | - | - |
| Total Debt | 0 | 864.49K | 2.14M |
| Total Equity | 55.13M | 31.05M | -15.77M |
| Shares Outstanding | 141.41M | 141.41M | 141.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -7.27M | -7.72M | -9.90M |
| Investing Cash Flow | -1.02M | -120.88K | -437.18K |
| Financing Cash Flow | 12.54M | 1.85M | 6.59M |
| Capital Expenditure | -232.31K | -120.88K | -437.18K |
| Free Cash Flow | -7.50M | -7.84M | -10.34M |
| Net Change in Cash | 4.25M | -5.99M | -3.75M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | 66.0% |
| Operating Margin % | - | - | -282,662.7% |
| Net Margin % | - | - | -284,359.2% |
| ROE % | -30.0% | -90.6% | 422.5% |
| ROCE % | -18.4% | -35.2% | -89.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VRXA
VERAXA Taps 20-Year Antibody Expert to Guide New Cancer Treatments - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOa1g3RFdTeXNUaWtfd0dfNnB5VTBKTnJySmRMMV9BZndEX1kwaGV0RnZ3MnlNMVB6Tk1oZnFDRTIwV1JXMkNQaC15VjBDdUNKeFdwbWljUWlabUY3aGh6cEozR3Q3RExLRnc1R24zU3RjR1FFLXhwMlVENy1RRkx4OEhnSTZiTXR5RE42a2…
Enterprise value to revenue forward of Veraxa Biotech AG – NASDAQ:VRXA - TradingView
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxORXVEUU9fWjR1ZW9TSWhTVXdXbEJiTXM1UkRFYXFLTzNpZ1B0YTBUOW81bTRrR19ibUwxdjJiQTNtcnNiVC1UTHpNZW1iUldELTc4YngzM2tQbmFoSnNoT3ZpWE80dVFTT1JfdUtBNnZLUU5fR3J0eWxWeHJhdFZaMDFqSENiUlM1NVI5Tm…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1xRDRvWXZyVnRSeUtMa3RxZjZ0d1NOSEo3OURBemd0Q0FQVDN3N0pVRi1JSHlieDYxSlVZdjRfdTd6VEFPeXo4RXdPWm5SZ1J6?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
VRXA Price Today: Veraxa Biotech AG Stock Price, Quote & Chart | MEXC - MEXC
<a href="https://news.google.com/rss/articles/CBMiT0FVX3lxTE1MTGJXZ2dRRGpCeFhjZHFjeEVEcHlnSXZ1NmVEcWxuNTdIUHhpNGhVYUVSV0YyNWhmQUVrZklIRER0S3NPRFR4N0lWcTJ4M1k?oc=5" target="_blank">VRXA Price Today: Veraxa Biotech AG Stock Price, Quote & Cha…
VRXA: Veraxa Biotech AG - Comparative Chart - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE40OW8xaDVYY2FMV0xnQmJLZTl2LXc1VVY1c0tyT3FRVWlXV3B6Y1NXRVhSTlpHeVBsTzYyU3NGdkNzREdFMkFTMFYwYjByQkJjMGNVQmNpczhubDZKOGcxOGV4RDI4N1U?oc=5" target="_blank">VRXA: Veraxa Biotech AG - Co…
VERAXA Biotech (NASDAQ: VRXA) Completes Business Combination, Begins Trading on Nasdaq - USA Today
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPN3R2cU9WMkNZNmRXeGFOZkVRLXBicHE3VHZiazJzSmVEZmpaa0ZHc2tyNS1LRDN4Z1l4bGFOVUtWbXNjRFZjN29HOW9WdUF3OWRVYS0zdHhMcHYzOFlDYTJydC1hZ3IxY3huVmw3MFN5ZEVWbWhvQVVSY2dzaTQ2amRzN2hWWG9KVWxRRz…
VRXA — Frequently Asked Questions
What is the current share price of VRXA?
As of 2026-08-05 17:25 PDT, VRXA trades at $1.82 on NASDAQ/NYSE. Its 52-week range is $1.72 to $24.79.
What is the market capitalisation of VRXA?
VRXA has a market capitalisation of $257.36M on NASDAQ/NYSE.
What is the P/E ratio of VRXA?
VRXA trades at a trailing price-to-earnings (P/E) ratio of -9.15. Its price-to-book (P/B) ratio is -16.32.
Is VRXA a good stock to buy?
This page provides a data-driven analysis of VRXA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.